Pullar T, Hunter J A, Capell H A
Ann Rheum Dis. 1987 May;46(5):398-402. doi: 10.1136/ard.46.5.398.
We have investigated the influence of sulphasalazine, a second line antirheumatic drug, on the radiological progression of erosions in rheumatoid arthritis over a two year period in 41 patients. Hand radiograph scores deteriorated significantly over this period, but in a group of 31 patients in whom one year films were also available this deterioration was limited to the first year. This slowing of radiological deterioration was not related to 'normalisation' of the erythrocyte sedimentation rate (ESR). Compared with a 'control' group of 10 patients who had refused offers of second line therapy, sulphasalazine treated patients showed less deterioration over the two year period, and this difference was more marked than in previous studies of gold or penicillamine. No significant change was seen in large joint radiographs in sulphasalazine treated patients over two years, but this probably represents the poor sensitivity of the method of assessment. No significant correlation was seen between changes in inflammatory indices and slowing of radiological deterioration in erosion score. Thus sulphasalazine appears to slow the progression of radiological disease of the hands over the second year of treatment in a representative sample of patients who continue to receive treatment for two years.
我们对41例类风湿关节炎患者进行了为期两年的研究,以探讨二线抗风湿药物柳氮磺胺吡啶对类风湿关节炎骨质侵蚀放射学进展的影响。在此期间手部X线片评分显著恶化,但在一组31例有一年期X线片的患者中,这种恶化仅限于第一年。放射学恶化速度的减慢与红细胞沉降率(ESR)的“正常化”无关。与10例拒绝二线治疗的“对照”组患者相比,接受柳氮磺胺吡啶治疗的患者在两年期间病情恶化程度较轻,且这种差异比以往金制剂或青霉胺的研究更为显著。接受柳氮磺胺吡啶治疗的患者在两年内大关节X线片未见明显变化,但这可能是评估方法敏感性较差所致。炎症指标的变化与侵蚀评分放射学恶化减慢之间未见显著相关性。因此,在继续接受治疗两年的代表性患者样本中,柳氮磺胺吡啶似乎在治疗的第二年减缓了手部放射学疾病的进展。